Davis Polk advised the joint book-running managers and representatives of the underwriters on an SEC-registered public debt offering by Bristol-Myers Squibb Company of $750 million principal amount of its 1.600% notes due 2019 and $750 million principal amount of its 3.250% notes due 2027.

Headquartered in New York City, Bristol-Myers Squibb Company engages in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. Its products are sold worldwide, primarily to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. It manufactures products in the United States, Puerto Rico and in six foreign countries.

The Davis Polk corporate team included partner Richard D. Truesdell Jr. and associate Alice Z. Chen. The tax team included partner Po Sit and associate Jonathan Atkins. Counsel Betty Moy Huber provided environmental advice. The intellectual property and technology team included counsel David R. Bauer and associate Tilak Koilvaram. All members of the Davis Polk team are based in the New York office.

Copy link to share post